Dr. YoungSoo Kim joined UIC in 2017, with ten-year principal investigator background at Korea Institute of Science and Technology (KIST). Dr. Kim’s research has focused on the development of drug candidates and diagnostic tools for Alzheimer’s disease by elucidating the pathological mechanisms of neurodegeneration. Dr. Kim’s ultimate research goal is to provide practical benefits to patients who are suffering from this fatal neurological disorder by developing innovative therapeutics and diagnostics.
Dr. Kim has equipped and trained his lab to perform Alzheimer’s disease research from A to Z. As drug discovery often requires interdisciplinary investigations, his team is fully functional in bioorganic protein chemistry, high-throughput drug screening, learning and memory behavioral studies, and neuropathological investigations based on chemical neurobiology. So far, Dr. Kim has succeeded five licensing-out deals, including Alzheimer blood test and Alzheimer drug candidate.
Dr. Kim’s lab welcomes undergraduate students by offering research environments where students can conduct novel research, learn scientific writing skills, and discuss professional development.
Ph.D. in Chemistry, The Scripps Research Institute, 2006
B.A. in Biochemistry, New York University, 2001
Courses and Current Research Areas
Lab on Biochemistry and Molecular Biology
Current Research Areas
Therapeutics, Diagnostics and Pathological Mechanisms of Alzheimer’s disease
EMBO Molecular Medicine. 2017;9:61. Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice. Yang S-H, Lee DK, Shin J, Lee S, Baek S, Kim J, Jung H, Hah J-M, Kim Y*.
Scientific Reports. 2016;6:34165. Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil. Kim HY, Kim HV, Lee DK, Yang S-H, Kim Y*.
Scientific Reports. 2016;6:34922. Cell surface GRP78 as a biomarker and target for suppressing glioma cells. Kang BR, Yang S-H, Chung B-R, Kim W, Kim Y*.
Scientific Reports. 2016;6:20185. Age-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice. Cho SM, Lee S, Yang S-H, Kim HY, Lee MJ, Kim HV, Kim J, Baek S, Yun J, Kim D, Kim YK, Cho Y, Woo J, Kim TS, Kim Y*.
Nature Communications. 2015;6:8997. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques. Kim HY, Kim HV, Jo S, Choi SY, Lee CJ, Park JK, Kim DJ*, Kim Y*.
Scientific Reports. 2015;5:15703. Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model. Yang S-H, Kim J, Lee MJ, Kim Y*.
Cell Reports. 2015;12(8):1244-51. Amyloid-β oligomers may impair SNARE-mediated exocytosis by direct binding to syntaxin 1a. Yang Y, Kim J, Kim HY, Ryoo N, Lee S, Kim Y, Rhim H, Shin YK*.
Scientific Reports. 2014;4:7467. Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. Kim HY, Kim HV, Yoon JH, Kang BR, Cho SM, Lee S, Kim JY, Kim JW, Cho Y, Woo J, Kim Y*.
Scientific Reports. 2014;4:6777. Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model. Cho SM, Kim HV, Lee S, Kim HY, Kim W, Kim TS, Kim DJ, Kim Y*.
Nature Medicine. 2014;20(8):886-96. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, Bae JY, Kim T, Lee J, Chun H, Park HJ, Lee da Y, Hong J, Kim HY, Oh SJ, Park SJ, Lee H, Yoon BE, Kim Y, Jeong Y, Shim I, Bae YC, Cho J, Kowall NW, Ryu H, Hwang E, Kim D, Lee CJ*.